GLI3 anticorps

N° du produit ABIN452567

L’anticorps Souris Monoclonal anti-GLI3 a été validé pour EIA et IHC (fro). Il convient pour détecter GLI3 dans des échantillons de Humain.

Aperçu rapide pour GLI3 anticorps (ABIN452567)

Antigène: GLI3 (GLI Family Zinc Finger 3 (GLI3))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp GLI3 est non-conjugé

Application: Enzyme Immunoassay (EIA), Immunohistochemistry (Frozen Sections) (IHC (fro))

Clone: YPBH-1

Détail du produit anti-GLI3 anticorps

Réactivité croisée (Details): Species reactivity (tested):Human.

Attributs du produit: Synonyms: Benign Prostatic Hyperplasia

Purification: Affinity Chromatography on Protein G.

Immunogène: Highly purified Benign Prostatic Hyperplasia (BPH).

Isotype: IgM

Information d'application

Indications d'application: This Benign Prostatic Hyperplasia antibody is suitable for use in ELISA andImmunohistochemistry. It was nor reaction in non-prostate normal tissue, neither prostate malignant tissuepositive. This anti-BPH antibody can react with some of well-moderately differentialprostate normal tissue and very rarely react with poor differential prostate normal tissue.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Reconstitution: Restore with Double distillated water to adjust the final concentration to 1.0 mg/mL.

Buffer: 0.01 M PBS, pH 7.2 without preservatives.

Agent conservateur: Without preservative

Stock: -20 °C

Stockage commentaire: Store the antibody at -20 °C. After reconstitution, aliquot and store at -20 °C.
Shelf life: one year from despatch.

Date de péremption: 12 months

Détails sur GLI3

Antigène: GLI3 (GLI Family Zinc Finger 3 (GLI3))

Autre désignation: BPH

Sujet: Benign prostatic hyperplasia (BPH) is a disease of unknown etiology that significantly affects the quality of life in aging men. Histologic BPH may present itself either as symptomatic or asymptomatic in nature. Benign prostatic hyperplasia (BPH), also known as benign enlargement of the prostate (BEP), is a condition that characterized by an increase in prostate size due to the formation of large nodules in the periurethral region of the prostate. Common in middle-aged and elderly men, benign prostatic hyperplasia leads to an obstruction of the urethra, thus interfering with normal urine flow and causing an urgency to urinate, as well as a decrease in urine flow. In some instances, benign prostatic hyperplasia can lead to recurrent urinary tract infections, bladder stones and kidney failure. These more serious afflictions are a direct result of an increase in the bacterial count within the bladder, a common phenomenon when urine flow is compromised. While mild cases of benign prostatic hyperplasia can be treated by a simple decrease in fluid intake, moderate to severe cases generally require medical treatment in the form of oral drugs or prostate surgery.Synonyms: Benign Prostatic Hyperplasia

Pathways: Signalisation Hedgehog